MAGEA10 and urothelial carcinoma: In two recent studies, patients with advanced NSCLC, head and neck squamous cell carcinoma, melanoma, or urothelial carcinoma were treated with genetically engineered autologous T cells that express a high-affinity MAGE-A10-specific TCR targeting MAGE-A10-positive tumors in the context of HLA-A*02 (ADP-A2M10).